The regulatory approval in the European Union comes approximately six months after Novocure secured FDA approval of the system, which uses tumor-treating fields (TTFields) to kill cancer cells. Through non-invasive, wearable arrays, Optune Lua uses TTFields to exert physical forces on the electrically charged components of the dividing cancer cells.

“Optune Lua is an innovative and urgently needed new approach for treating metastatic non-small cell lung cancer,” Dr. Joachim Aerts, an investigator in the system’s Phase 3 LUNAR clinical trial and professor of pulmonary oncology at the Erasmus MC Cancer Institute.